The aim of the present study was to evaluate oxytocin and benign prostatic hyperplasia (BPH), and study the cell signalling mechanism. Investigation was performed in patients about the correlation between oxytocin level and BPH. Mice were injected with oxytocin or oxytocin antagonist for 2 weeks and the prostate morphology was studied after their sacrifice. Furthermore, in vitro experiments were performed to evaluate the oxytocin effect through the MEK/ERK/RSK pathway. Oxytocin was significantly elevated in the serum and prostate tissue of patients with BPH, and a positive correlation with prostate volume indicated. In the animal experiments, prostate enlargement was observed in the oxytocin-treated group, whereas oxytocin antagonist reduced prostate hyperplasia. The in vitro study confirmed this result and also revealed activation of the MEK/ERK/RSK pathway. Oxytocin is highly expressed in the serum and prostate tissue of patients with BPH. In addition, oxytocin aggravates BPH and the oxytocin-induced proliferative effect on prostatic cells is mediated through the MEK/ERK/RSK pathway, at least partly. Thus, the hypothalamic regulation may be involved in development of BPH, which may open a new door to more medications for BPH in the future.
Oxytocin: its role in benign prostatic hyperplasia via the ERK pathway
- Views Icon Views
- Share Icon Share
Huan Xu, Shi Fu, Yanbo Chen, Qi Chen, Meng Gu, Chong Liu, Zhiguang Qiao, Juan Zhou, Zhong Wang; Oxytocin: its role in benign prostatic hyperplasia via the ERK pathway. Clin Sci (Lond) 1 April 2017; 131 (7): 595–607. doi: https://doi.org/10.1042/CS20170030
Download citation file: